Emerging Company Profile
Quell: tweaking Tregs for persistence, potency and stability
Emerging Company Profile: Syncona’s Quell is developing more targeted Treg cell therapies
Backed by Syncona, London-based Quell is among a new generation of companies springboarding off advances in CAR T cells and gene editing to develop more targeted Treg cell therapies.
Feb 12, 2021 | 1:18 AM GMT